stockrow
Saturday 7 November 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024.
- Revenue
- +16.0%
- EPS
- +30.8%
- Free cash flow
- +36.5%
- Total debt
- +138.5%
Quarter to September 2026, against a year earlier
2.79
0.14
+5.28%
Follow SPRY
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.52 | 6.80 | 8.06 | 13.63 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(12.74) | (13.06) | (17.74) | (26.41) | |
P/B ratio |
0.00 | 63.58 | 13.01 | 10.05 | |
Price to Tangible BV |
0.00 | 0.00 | 16.92 | 11.51 | |
EV/Sales |
3.79 | 7.05 | 7.76 | 12.72 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.53) | (4.19) | (4.39) | (6.28) | |
EV/FCF |
(2.33) | (3.88) | (4.03) | (5.75) | |
Quick Ratio |
2.94 | 3.13 | 4.63 | 6.91 | |
Current Ratio |
3.25 | 3.48 | 4.94 | 7.28 | |
Net Debt/EBITDA |
0.00 | (0.45) | 0.49 | 1.82 | |
Debt/Assets |
0.00% | 68.78% | 59.53% | 51.43% | |
Debt/Equity |
0.00 | 13.72 | 2.79 | 1.47 | |
Asset Turnover |
0.39 | 0.42 | 0.32 | 0.25 | |
Operating CF/Net income |
0.00 | 0.98 | 0.74 | 1.05 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 3.41 | |
Interest Coverage |
— | (24.79) | (24.64) | — | |
Research and Development Expense of Revenue |
48.43% | 13.96% | 19.12% | 12.26% | |
Selling, General and Administrative Expense of Revenue |
115.41% | 230.49% | 318.35% | 213.46% | |
Intangible Assets out of Total Assets |
0.05 | 0.06 | 0.05 | 0.04 | |
Share Based Compensation of Revenue |
21.54% | 36.83% | 32.73% | 20.43% | |
Graham Net Nets |
(0.12) | (0.03) | 0.02 | 0.06 | |
Graham Number |
2.33 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(46.87%) | (27.22%) | (25.03%) | (15.02%) | |
Free Cash Flow Yield |
(46.26%) | (26.66%) | (23.93%) | (16.25%) | |
Revenue per Share |
0.38 | 0.34 | 0.23 | 0.29 | |
Operating CF per Share |
(0.34) | (0.61) | (0.45) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.34) | (0.61) | (0.45) | (0.46) | |
Cash per Share |
1.39 | 1.45 | 2.02 | 2.49 | |
Shareholders Equity per Share |
(0.12) | 0.13 | 0.62 | 1.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.12) | 0.13 | 0.62 | 1.16 | |
Free Cash Flow |
(33.71) | (60.93) | (44.95) | (45.48) | |
Working Capital |
146.13 | 150.65 | 195.62 | 245.75 | |
Capital Expenditures |
— | — | — | (2.00) | |
Net Current Asset Value |
(52.41) | (25.47) | 18.97 | 71.50 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
44.60 | 35.98 | 18.98 | 16.76 | |
Average Payables |
56.78 | 52.00 | 37.64 | 30.39 | |
Average Inventory |
— | 10.21 | 8.04 | 6.79 | |
Average Assets |
312.14 | 281.48 | 307.44 | 339.40 | |
Average Common Equity |
67.85 | 102.42 | 145.14 | 185.53 |
Columns are period end dates · fundamentals updated 5 Nov 2026